Caracterización de pacientes hospitalizados con neoplasia activa y diagnóstico de enfermedad tromboembólica venosa mediante la puntuación de Khorana en el Instituto Nacional del Cáncer

Translated title of the contribution: Khorama score as a predictive tool for thromboembolic events in high risk patients

Verónica Kramer*, Macarena Klein, Fernando Cevallos, Marcela Cárcamo

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Background: There is an established relation between cancer and the development of thromboembolic venous disease. Khorana et al developed a predictive score using clinical characteristics and laboratory values to stratify patients according to their risk. Aim: To characterize using Khorana score, patients with active cancer and a diagnosis of thromboembolic disease during hospitalization in an oncology hospital. Material and Methods: Review of records of the pharmacy of the hospital, selecting patients who received heparin in therapeutic doses during their hospitalization. Using laboratory values available in the medical records, the Khorama score was calculated. Results: Twenty seven patients with thromboembolic events, aged 60 ± 2 years (56% males) were selected for the study. Eighty percent of them were catalogued in the intermediate and high risk group according to Khorana score. Conclusions: Khorana score is a simple scale that might be useful to establish early prophylactic measures in patients with high risk for thromboembolic events, especially those with cancer.

Translated title of the contributionKhorama score as a predictive tool for thromboembolic events in high risk patients
Original languageSpanish
Pages (from-to)593-597
Number of pages5
JournalRevista Medica de Chile
Issue number5
StatePublished - May 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016, Sociedad Medica de Santiago. All Rights Reserved.


Dive into the research topics of 'Khorama score as a predictive tool for thromboembolic events in high risk patients'. Together they form a unique fingerprint.

Cite this